Langerhans Cell Histiocytosis clinical trials at UC Davis
2 research studies open to eligible people
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
open to eligible people ages 12 months to 21 years
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations that have spread to other places in the body and have come back or do not respond to treatment. Erdafitinib may stop the growth of cancer cells with FGFR mutations by blocking some of the enzymes needed for cell growth.
Sacramento, California and other locations
Project: Every Child for Younger Patients With Cancer
“A REGISTRY, ELIGIBILITY SCREENING, BIOLOGY AND OUTCOME STUDY”
open to eligible people ages up to 25 years
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Sacramento, California and other locations